teclistamab
genmab,janssen
['majestec-1', 'mmsm', 'multiple myeloma', 'teclistamab']
i have been asked several questions about the #asco23 abstract: durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majestec-1 study (8034), wanted to create a for #mmsm 
Chief of Myeloma @MSKCancerCenter | Chair @ALLIANCE_org #mmsm Comm. |Physician ≠ Provider| @ASH_hematology @ASTCT @ASCO |married to @ZainabShd | #BMTsm #CARTsm